Treatment-related adverse events (N=13)
| All cohorts | ||||
| Adverse event | All grades N (%) | Grade 1 N (%) | Grade 2 N (%) | Grade ≥3 n (%) |
| Fatigue | 11 (85) | 5 (39) | 4 (31) | 2 (15) |
| Injection-site pain | 9 (69) | 7 (54) | 2 (15) | - |
| Fever | 8 (62) | 5 (39) | 3 (23) | - |
| Nausea | 8 (62) | 7 (54) | – | 1 (8) |
| Chills | 6 (46) | 3 (23) | 3 (23) | - |
| Influenza-like symptoms | 6 (46) | 5 (39) | 1 (8) | - |
| Abdominal pain | 5 (39) | 5 (39) | - | - |
| Redness at injection-site | 4 (31) | 4 (31) | – | - |
| Headache | 4 (31) | 3 (23) | 1 (8) | – |
| Myalgia | 3 (23) | 3 (23) | – | - |
| Malaise | 3 (23) | 3 (23) | – | – |
| Pruritus (generalized) | 3 (23) | 2 (15) | 1 (8) | – |
| Transpiration | 3 (23) | 1 (8) | 2 (15) | – |
| Diarrhea | 3 (23) | 3 (23) | – | – |
| Inflammatory syndrome | 2 (15) | – | 1 (8) | 1 (8) |
| Hyperkalemia | 2 (15) | 2 (15) | – | – |
| Liver enzyme elevation | 2 (15) | 2 (15) | – | – |
| Eosinophilia | 1 (8) | – | – | 1 (8) |
| Purpuric rash | 1 (8) | 1 (8) | – | - |
| Arterial hypertension | 1 (8) | – | – | 1 (8) |
| Blurry vision | 1 (8) | 1 (8) | – | - |
| Acute kidney injury | 1 (8) | – | – | 1 (8) |
| Pruritus (localized) | 1 (8) | 1 (8) | – | – |
| Local hemorrhage | 1 (8) | 1 (8) | – | – |
| Vertigo | 1 (8) | 1 (8) | – | – |
| Rash (local) | 1 (8) | 1 (8) | – | – |
| Hematoma (local) | 1 (8) | 1 (8) | – | – |
| Inflammation/hemorrhage (local) | 1 (8) | 1 (8) | – | – |
| Photophobia | 1 (8) | 1 (8) | – | – |